Volume 4, Issue 3
Editorialp. 195–197
Co-morbidities and their underappreciated impact on the conversion of oncology trial results into routine clinical practice
Author(s): Maurie Markman
Editorialp. 199–200
Research integrity in the modern era: current gaps in our knowledge and thinking
Author(s): Marisa Kardos Garshick and Alexa Boer Kimball
Editorialp. 201–203
The therapeutic potential of glucagon-like peptide-1 analogs in the treatment of Alzheimers disease
Author(s): Grazia D Femminella & Paul Edison
News and Viewsp. 205–208
CHILD-INNOVAC project demonstrates effective nasal vaccine against pertussis in Phase I trial
Research Updatep. 209–214
The UK Dermatology Clinical Trials Network: how far have we come?
Author(s): Carron Layfield, Adrian Yong, Kim Thomas and Hywel Williams
Commentaryp. 221–225
An update on clinical trials in Charcot-Marie-Tooth Disease
Author(s): Davide Pareyson & Giuseppe Piscosquito
Special Reportp. 227–234
Estimating site costs prior to conducting clinical trials
Author(s): Dorothee Arenz, Barbara Hero, Barbara F Eichhorst, Martin Langer, Lars Pester, Julia von Tresckow, Jrg J Vehreschild, Maria JGT Vehreschild, Oliver A Cornely
Review: Clinical Trail Outcomesp. 235–245
A review of the long-term outlook of children and young people post liver transplant
Author(s): Nicola Ruth & Deirdre Kelly
Review: Clinical Trail Outcomesp. 247–257
Outcomes of novel trials for cancer cachexia
Author(s): Rony Dev, Egidio Del Fabbro, Eduardo Bruera
Review: Clinical Trail Outcomesp. 259–267
Betamethasone valerate foam: a look at the clinical data
Author(s): Avner Shemer, Nicole Sakka & Dov Tamarkin
Review: Clinical Trail Outcomesp. 269–279
Ibudilast for the treatment of drug addiction and other neurological conditions
Author(s): Kirk W Johnson, Kazuko Matsuda & Yuichi Iwaki
Review: Clinical Trail Outcomesp. 281–286
OnabotulinumtoxinA for the treatment of overactive bladder
Author(s): Altaf Mangera & Christopher R Chapple
Corrigendump. 288
